Prostate specific antigen
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Kallikrein-related peptidase 3
| ||||||||||||||
| Identifiers | ||||||||||||||
| Symbol(s) | KLK3; APS; KLK2A1; PSA; hK3 | |||||||||||||
| External IDs | OMIM: 176820 MGI: 892021 Homologene: 84789 | |||||||||||||
| ||||||||||||||
| RNA expression pattern | ||||||||||||||
|
| ||||||||||||||
| Orthologs | ||||||||||||||
| Human | Mouse | |||||||||||||
| Entrez | 354 | 16617 | ||||||||||||
| Ensembl | ENSG00000142515 | ENSMUSG00000063713 | ||||||||||||
| Uniprot | P07288 | O35307 | ||||||||||||
| Refseq | NM_001030047 (mRNA) NP_001025218 (protein) | XM_001000656 (mRNA) XP_001000656 (protein) | ||||||||||||
| Location | Chr 19: 56.05 - 56.06 Mb | Chr 7: 44.06 - 44.06 Mb | ||||||||||||
| Pubmed search | [1] | [2] | ||||||||||||
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Prostate specific antigen (PSA) is a protein produced by the cells of the prostate gland. PSA is present in small quantities in the serum of normal men, and is often elevated in the presence of prostate cancer and in other prostate disorders. A blood test to measure PSA is the most effective test currently available for the early detection of prostate cancer. Higher than normal levels of PSA are associated with both localized and metastatic prostate cancer (CaP).
Biochemistry
Prostate specific antigen (PSA), also known as kallikrein III, seminin, semenogelase, γ-seminoprotein and P-30 antigen) is a 34 kD glycoprotein manufactured almost exclusively by the prostate gland; PSA is produced for the ejaculate where it liquifies the semen and allows sperm to swim freely.[1] It is also believed to be instrumental in dissolving the cervical mucous cap, allowing the entry of sperm.[1]
Biochemically it is a serine protease (EC 3.4.21.77) enzyme, the gene of which is located on the nineteenth chromosome (19q13). [1]
Clinical significance
Serum PSA
PSA is normally present in the blood at very low levels. The reference range of 0-4.0 ng/mL for the first commercial PSA test, the Hybritech Tandem-R PSA test released in February 1986, was based on a study that found 99% of 472 apparently healthy men had a total PSA level below 4 ng/mL—the upper limit of normal is much less than 4 ng/mL.[1] Increased levels of PSA may suggest the presence of prostate cancer. However, prostate cancer can also be present in the complete absence of an elevated PSA level, in which case the test result would be a false negative.[1]
PSA levels can be also increased due to prostate infection, irritation, benign prostatic hypertrophy (enlargement) or hyperplasia (BPH), recent ejaculation,[1] or digital rectal examination (DRE),[1] in which case it may give a false positive.[1]
Despite earlier findings,[1] recent research suggests that the rate of increase of PSA (the PSA velocity) is not a more specific marker for prostate cancer.[1] However, the PSA rate of rise may have value in prostate cancer prognosis. Men with prostate cancer whose PSA level increased by more than 2.0 ng per milliliter during the year before the diagnosis of prostate cancer have a higher risk of death from prostate cancer despite undergoing radical prostatectomy.[1]
Most PSA in the blood is bound to serum proteins. A small amount is not protein bound and is called free PSA. In men with prostate cancer the ratio of free (unbound) PSA to total PSA is decreased. The risk of cancer increases if the free to total ratio is less than 25%. (See graph at right.) The lower the ratio the greater the probability of prostate cancer. Measuring the ratio of free to total PSA appears to be particularly promising for eliminating unnecessary biopsies in men with PSA levels between 4 and 10 ng/mL.[1] However, both total and free PSA increase immediately after ejaculation, returning slowly to baseline levels within 24 hours.[1]
Tissue PSA
In addition to measuring the PSA in blood, tissue samples can be stained for the presence of PSA in order to determine the origin of maligant cells that have metastasized.[1]
Prostate cancer screening
The U.S. Food and Drug Administration (FDA) has approved the PSA test for annual screening of prostate cancer in men of age 50 and older. PSA levels between 4 and 10 ng/mL (nanograms per milliliter) are considered to be suspicious and should be followed by rectal ultrasound imaging and, if indicated, prostate biopsy. PSA is false positive-prone (7 out of 10 men in this category will still not have prostate cancer) and false negative-prone (2.5 out of 10 men with prostate cancer have no elevation in PSA).[1] Recent reports indicate that refraining from ejaculation 24 hours or more prior to testing will improve test accuracy.[1]
See also
References
Further reading
- De Angelis G, Rittenhouse HG, Mikolajczyk SD, Blair Shamel L, Semjonow A (2007). "Twenty Years of PSA: From Prostate Antigen to Tumor Marker". Reviews in urology 9 (3): 113–23. PMID 17934568.
- Henttu P, Vihko P (1994). "Prostate-specific antigen and human glandular kallikrein: two kallikreins of the human prostate.". Ann. Med. 26 (3): 157-64. PMID 7521173.
- Diamandis EP, Yousef GM, Luo LY, et al. (2001). "The new human kallikrein gene family: implications in carcinogenesis.". Trends Endocrinol. Metab. 11 (2): 54-60. PMID 10675891.
- Lilja H (2003). "Biology of prostate-specific antigen.". Urology 62 (5 Suppl 1): 27-33. PMID 14607215.
External links
- American Cancer Society: Detailed Guide: Prostate Cancer Can Prostate Cancer Be Found Early?
- National Cancer Institute: The Prostate-Specific Antigen (PSA) Test: Questions and Answers
- MeSH Prostate-Specific+Antigen
- Prostate-Specific+Antigen at eMedicine Dictionary
Tumor markers |
|---|
| Alpha-fetoprotein/AFP-L3 - CA-125 - CA 19-9 - CD30 - Autocrine motility factor - Carcinoembryonic antigen - βHCG - erbB-2 receptor - erbB-3 receptor - NANOG - Neprilysin - Normetanephrine - PCNA - Prostate specific antigen - Synaptophysin |
hr:Antigen specifičan za prostatu it:Semenogelasi nl:Prostaatspecifiek antigen ja:前立腺特異抗原sv:Prostataspecifikt antigen
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
